Table 1.
Clinical and tumor characteristics of patients included in the study
| Variable | Overall (110) |
| Age (yr) | 67.5 (41-80) |
| Gender | |
| Male | 91 (82.7) |
| Female | 19 (17.3) |
| Etiology of liver disease | |
| Viral (HBV/HCV/HBV and HCV) | 70 (63.6) |
| Alcohol | 17 (15.5) |
| NASH/NAFLD | 14 (12.7) |
| Viral and alcohol | 9 (8.2) |
| PS | |
| 0 | 33 (30) |
| 1 | 64 (58.2) |
| 2 | 13 (11.8) |
| Diabetes | |
| No | 87 (79.1) |
| Yes | 23 (20.9) |
| Child-Pugh score | |
| A | 82 (74.5) |
| B | 28 (25.5) |
| N nodules | |
| Single | 35 (31.8) |
| 2-3 | 20 (18.2) |
| > 3 or infiltrating | 55 (50) |
| Maximum size | |
| ≤ 5 cm | 56 (50.9) |
| > 5 cm | 54 (49.1) |
| Macrovascular invasion | |
| No | 60 (54.5) |
| Yes | 50 (45.5) |
| Extrahepatic spread | |
| No | 91 (82.7) |
| Yes | 19 (17.3) |
| Macrovascular invasion and/or extrahepatic spread | |
| No | 49 (44.5) |
| Yes | 61 (55.5) |
| NIACE | |
| ≤ 3 | 84 (76.4) |
| > 3 | 26 (23.6) |
| AFP | |
| ≤ 200 ng/mL | 74 (67.3) |
| > 200 ng/mL | 36 (32.7) |
| Treatment before BCLC C diagnosis | |
| No | 53 (48.2) |
| Yes | 57 (51.8) |
| Type of treatment before BCLC C diagnosis (one or more per patient) | |
| TACE | 35 |
| Surgical resection | 20 |
| RFA | 18 |
| Sorafenib | 13 |
| PEI | 11 |
| TACE + RFA | 8 |
| TARE | 4 |
| DSM-TACE | 1 |
| Number of treatments after BCLC C diagnosis | |
| None | 22 (20) |
| Single | 32 (29.1) |
| Multiple | 56 (50.9) |
| Type of treatment after BCLC C diagnosis (one or more per patient) | |
| Sorafenib | 53 |
| TACE | 25 |
| TARE | 18 |
| Second line systemic agent | 15 |
| PEI | 12 |
| DSM-TACE | 5 |
| LT | 3 |
| RFA | 1 |
| Best tumor response | |
| CR | 10 (9.1) |
| PR | 21 (19.1) |
| SD | 12 (10.9) |
| PD | 67 (60.9) |
| DC | |
| No | 67 (60.9) |
| Yes | 43 (39.1) |
Continuous variables are reported as median value and range, categorical variables as frequencies and percentage. HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Nonalcoholic Steatohepatitis; NAFLD: Nonalcoholic fatty liver disease; PS: Performance status; AFP: Alphafetoprotein; DC: Disease control; TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization; DSM-TACE: Degradable starch microspheres transarterial chemoembolization; PEI: Percutaneous ethanol injection; RFA: Radiofrequency ablation; LT: Liver transplant; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; DC: Disease control.